The Cancer Center picks ATCi's Simulsat broadcast system to extend its critical broadcast applications

NewsGuard 100/100 Score

Antenna Technology Communications Inc., a provider of satellite communications systems, today announced that one of the largest university-based cancer research centers has selected the ATCi Simulsat C/Ku Multibeam antenna solution and related satellite equipment to outfit its central headquarters.

The Cancer Center chose the Simulsat broadcast system because of the antenna's ability to receive programming from up to 35 satellites simultaneously without degradation of quality across each signal. With a 70-degree longitude satellite view arc, Simulsat C/Ku can receive a variety of "C" and Ku-band satellite programming data. Essentially, one Simulsat C/Ku does the work of 35 steerable parabolic antennas and only requires the space of one and a half antennas.

ATCi provided and handled the complete installation of the Simulsat C/Ku Multibeam System, two 5 meter steerable antennas and a complete fiberoptic system to meet the broadcast needs of the Cancer Center.

ATCi's CEO Gary Hatch noted that the company's Simulsat C/Ku Multibeam specifically was re-engineered to handle the unique applications that are specific to broadcasters in this arena.

"We are proud to have been selected by the Cancer Center to assist in their continuing effort to expand the hospital's critical broadcast applications for such a crucial cause," said Gary Hatch, ATCi's CEO. "This clearly shows ATCi's commitment to deliver best-of-breed solutions to the ever-changing communications industry. With Simulsat's ability to receive programming from up to 35 satellites, the Cancer Center will be able to access an exceptionally diverse amount of programming that far surpasses the satellite reception capabilities of any other competing system."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases